P0097Wearable perspiration sensor for continuous inflammation tracking in Inflammatory Bowel Disease

Background Wearable sensors present an opportunity to monitor inflammation via noninvasive media such as perspiration, which may be sampled continuously to track inflammation-related markers in patients with inflammatory bowel disease (IBD). Here, we demonstrate the use of a perspiration sensor for C-reactive protein (CRP) and calprotectin, and the important clinical significance of these markers. Methods We performed a cross-sectional study of adult IBD patients’ CRP and calprotectin expression in perspiration compared to clinically relevant expression of these markers in serum and stool, respectively. Perspiration on-body measurements were obtained every minute using a proprietary wearable sensor worn for 40-130 minutes during a standard of care assessment. Synchronously collected serum levels were measured, as were fecal calprotectin (FCP) levels from a subset of the cohort. Results A total of 33 patients with IBD were included. Principal component analysis (PCA) of demographic data identified age, disease status, and diagnosis as the strongest corresponding variables. PCA of the subcohort whose FCP was measured identified endoscopic score as the strongest corresponding variable (Figure 1). In perspiration and serum, median CRP was observed to be elevated in patients with CD over UC, while median calprotectin was elevated in UC over CD. Median perspiration, serum, and FCP were observed to be elevated in patients with colitis compared to patients with ileitis. Median perspiration and serum CRP were observed to be elevated in patients <40 years of age compared to patients >40 years of age. Median perspiration, serum, and FCP were elevated in patients >40 years of age compared to patients <40 years of age. Conclusion We report the use of a noninvasive perspiration-based sensor for tracking inflammatory markers in patients with IBD. Our findings demonstrate consistency of measurements of perspiration CRP and calprotectin compared with corresponding serum and stool measurements, thereby supporting the utility of our perspiration sensor for noninvasive IBD monitoring. Conflict of interest: Ms. Shahub, Sarah: No conflict of interest Lin, Kai-Chun: No conflict of interest Choi, Natalie: No conflict of interest Garcia, Nicole: No conflict of interest Muthukumar, Sriram: Sriram Muthukumar has a shareholder interest in Enlisense LLC, a company that may have a commercial interest in the results of this research and technology. The potential individual conflict of interest has been reviewed and managed by The University of Texas at Dallas and played no role in the study design in the collection, analysis, and interpretation of data in the writing of the report or in the decision to submit the report for publication. Rubin, David T.: Consultant/Advisor: Abbvie, Abivax SA, Altrubio, Athos Therapeutics Inc, Bristol-Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, Ventyx Grant support: Takeda, Helmsley Charitable Trust, NIH P30 DK42086, Gastro-Intestinal Research Foundation, NIH R01 PAS-23-086 Board of Trustees/Board of Directors: Cornerstones Health Prasad, Shalini: Shalini Prasad has a shareholder interest in Enlisense LLC, a company that may have a commercial interest in the results of this research and technology. The potential individual conflict of interest has been reviewed and managed by The University of Texas at Dallas and played no role in the study design in the collection, analysis, and interpretation of data in the writing of the report or in the decision to submit the report for publication.